Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.

Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.

<h4>Objective</h4>The aim of this pilot study was to explore intrapatient mixed metabolic response and early 18F-FDG PET response evaluation using predefined quantification strategies in patients with advanced KRAS wild-type colorectal adenocarcinoma (mCRC) treated with cetuximab.<h4&...

Full description

Saved in:

Bibliographic Details
Main Authors:	Erik J van Helden, Otto S Hoekstra, Ronald Boellaard, Chantal Roth, Emma R Mulder, Henk M W Verheul, C Willemien Menke-van der Houven van Oordt
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155178&type=printable
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Validating image-derived input functions of dynamic 18F-FDG long axial field-of-view PET/CT studies
by: Charlotte L. C. Smith, et al.
Published: (2025-02-01)

The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study
by: Niels J. van Ruitenbeek, et al.
Published: (2025-07-01)

Extraskeletal osteosarcoma: An uncommon variant with rare metastatic sites detected with FDG PET/CT
by: Ameya D. Puranik, et al.
Published: (2014-01-01)

The value of fdg pet/ct for dıagnosıng metastatıc ınfectıons ın staphylococcus aureus bacteremıa
by: Elif Mukime Sarıcaoglu, et al.
Published: (2024-12-01)

FDG PET/CT in Detection of Metastatic Involvement of Heart and Treatment Monitoring in Non-Hodgkin′s Lymphoma
by: Kanhaiyalal Agrawal, et al.
Published: (2012-01-01)

Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors
by: Hanna Saadani, et al.
Published: (2025-07-01)

Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by 18F-BMS-986192 PET: pooled analysis of data from four solid tumor types
by: Tanja D de Gruijl, et al.
Published: (2024-06-01)

Kidney Modelling for FDG Excretion with PET
by: Huiting Qiao, et al.
Published: (2007-01-01)

Potential of non-FDG PET radiotracers for paediatric patients with solid tumours
by: Leonor Teles, et al.
Published: (2024-12-01)

Impact of neoadjuvant systemic therapy on surgical and radiotherapy outcomes in patients with early-stage breast cancer: a cross-sectional retrospective single-center study
by: Yasmin A. Civil, et al.
Published: (2025-07-01)

Recent Updates of PET in Lymphoma: FDG and Beyond
by: Sung-Yong Kim, et al.
Published: (2024-10-01)

Incidence of Abnormal FDG-PET in Partial Epilepsy
by: J Gordon Millichap
Published: (2002-03-01)

COMPARISON BETWEEN 18F-PSMA AND 18F-FDG RADIOTRACERS FOR PET/CT IN THE EVALUATION OF PATIENTS WITH METASTATIC MELANOMA
by: Thiago Soare Rocha Alves, et al.
Published: (2025-05-01)

FDG PET/CT AND PSMA PET/CT IN MUSCULOSKELETAL SOFT TISSUE SARCOMAS
by: Ellen Nogueira Lima, et al.
Published: (2025-05-01)

The Role of [<sup>18</sup>F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas
by: Stijn J.C. van der Burg, et al.
Published: (2025-04-01)

18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma
by: Tine Gadegaard Hindso, et al.
Published: (2025-02-01)

Quantification of FDG in the spinal cord using PET/MRI
by: Eve Lennie, et al.
Published: (2025-08-01)

[18F]-FDG PET-CT in Malignant Melanoma
by: Teodora Sidonia Mititelu, et al.
Published: (2025-05-01)

FDG-PET assessment of the locus coeruleus in Alzheimer’s disease
by: Kathy Y. Liu, et al.
Published: (2021-03-01)

18F-FDG-PET/CT for polymyalgia rheumatica: agreement and diagnostic accuracy of routine PET scan report vs. standardized PMR PET scores
by: Kornelis S. M. van der Geest, et al.
Published: (2025-03-01)

Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma
by: Bernies van der Hiel, et al.
Published: (2025-05-01)

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma
by: Sydney Ch’ng, et al.
Published: (2025-03-01)

18FDG PET/CT is sensitive but not specific for malignancy: two cases of disseminated tuberculosis mimicking metastatic cancer on imaging and clinical presentation
by: Maxime Collin, et al.
Published: (2025-06-01)

Prediction of EGFR mutations in non-small cell lung cancer: a nomogram based on 18F-FDG PET and thin-section CT radiomics with machine learning
by: Jianbo Li, et al.
Published: (2025-04-01)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
by: M. André, et al.
Published: (2011-01-01)

FDG‐PET patterns associate with survival in patients with prion disease
by: Nick Corriveau‐Lecavalier, et al.
Published: (2024-12-01)

Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in breast cancer recurrence: a systematic review and meta-analysis
by: Shiqing Liu, et al.
Published: (2025-08-01)

Dedifferentiated liposarcoma lung metastases with different FDG-PET/CT findings
by: Yoshito Imamura, et al.
Published: (2023-05-01)

Denosumab-Induced Osteonecrosis of the Jaw with FDG PET/CT imaging features.
by: SALONI RAJKOTIA, et al.
Published: (2024-11-01)

18F-FDG PET-CT in Fitz-Hugh-Curtis Syndrome
by: Teik Hin Tan, et al.
Published: (2022-06-01)

Non-[<sup>18</sup>F]FDG PET-Radiopharmaceuticals in Oncology
by: Antonia Dimitrakopoulou-Strauss, et al.
Published: (2024-12-01)

Properties of S. aureus spondylodiscitis in CT and F18-FDG-PET/CT
by: J. Hockmann, et al.
Published: (2024-01-01)

Utility of FDG PET/CT in Sjögren’s Syndrome and associated lymphomas; Lymphomagenesis
by: Dikhra Khan, et al.
Published: (2025-01-01)

Mild SARS-CoV-2 Infection with the Omicron Variant Mimicking Metastatic Cancer on Whole-Body 18-F FDG PET/CT Imaging
by: Gunnhild Helmsdal, et al.
Published: (2025-06-01)

Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients
by: Marc Bertaux, et al.
Published: (2025-05-01)

Assessing the metabolism of the olfactory circuit by use of 18F-FDG PET-CT imaging in patients suspected of suffering from Alzheimer’s disease or frontotemporal dementia
by: Daniël S. L. Loewenstein, et al.
Published: (2024-10-01)

Diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in preoperative staging of locoregional urinary bladder cancer: a systematic review and Meta-Analysis
by: Ahmed Saad Abdlkadir, et al.
Published: (2025-07-01)

[18F]FDG PET/CT versus [18F]FDG PET/MRI in staging of non-small cell lung cancer: a head-to-head comparative meta-analysis
by: Dandan Yu, et al.
Published: (2025-01-01)

Preoperative partial breast reirradiation and repeat breast-conserving surgery in patients with recurrent breast cancer: the prospective single-arm REPEAT trial – a study protocol
by: Ellis Barbé, et al.
Published: (2025-07-01)

Impact of routine FDG-PET/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapy
by: Jetske L.B. Gunster, et al.
Published: (2025-06-01)